Targeted Disease(s):
Lung Cancer
Purpose of Study:
To compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Study Dates:
January 1, 2021 - July 1, 2022
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Takeda
ClinicalTrails.gov Identifier:
NCT04129502
